| P2093 | author name string | Michael Croft | |
| | Carl F Ware | |
| | Chris A Benedict | |
| P2860 | cites work | Denosumab-mediated increase in hand bone mineral density associated with decreased progression of bone erosion in rheumatoid arthritis patients | Q84062765 |
| | Upregulation and nuclear localization of TNF‐like Cytokine 1A (TL1A) and its receptors DR3 and DcR3 in psoriatic skin lesions | Q84358114 |
| | Efficacy and safety of tanezumab in the treatment of chronic low back pain | Q84421146 |
| | SOX40L: an important inflammatory mediator in adult bronchial asthma | Q84516949 |
| | TNF receptor 1 genetic risk mirrors outcome of anti-TNF therapy in multiple sclerosis | Q24293476 |
| | Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia | Q24594920 |
| | Atacicept: targeting B cells in multiple sclerosis | Q24628925 |
| | T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia | Q24632975 |
| | Hodgkin lymphoma cells express TACI and BCMA receptors and generate survival and proliferation signals in response to BAFF and APRIL | Q24681342 |
| | Expression of silencer of death domains and death-receptor-3 in normal human kidney and in rejecting renal transplants | Q24685457 |
| | Circulating levels of TNF-like cytokine 1A (TL1A) and its decoy receptor 3 (DcR3) in rheumatoid arthritis | Q81895285 |
| | Clinical association of serum CD137 (4-1BB) levels in patients with systemic sclerosis | Q82220201 |
| | A phase I weekly dosing study of brentuximab vedotin in patients with relapsed/refractory CD30-positive hematologic malignancies | Q82489143 |
| | Preclinical characterization of SGN-70, a humanized antibody directed against CD70 | Q82791833 |
| | A phase I safety and pharmacokinetic study of the death receptor 5 agonistic antibody PRO95780 in patients with advanced malignancies | Q82847250 |
| | Intravenous and intradermal TriMix-dendritic cell therapy results in a broad T-cell response and durable tumor response in a chemorefractory stage IV-M1c melanoma patient | Q82901856 |
| | Glucocorticoid-induced tumor necrosis factor receptor family-related protein exacerbates collagen-induced arthritis by enhancing the expansion of Th17 cells | Q83169803 |
| | TNFSF9 expression in primary biliary cirrhosis and its clinical significance | Q83372673 |
| | The involvement of epithelial Fas in a human model of graft versus host disease | Q83610928 |
| | Atacicept in patients with rheumatoid arthritis and an inadequate response to methotrexate: Results of a phase II, randomized, placebo-controlled trial | Q83753641 |
| | Phase I Study of Atacicept in Relapsed/Refractory Multiple Myeloma (MM) and Waldenström's Macroglobulinemia | Q83757871 |
| | Anti-NGF painkillers back on track? | Q84032456 |
| | A human anti-CD40 monoclonal antibody, 4D11, for kidney transplantation in cynomolgus monkeys: induction and maintenance therapy | Q84056960 |
| | Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial | Q78667363 |
| | Anti-OX40 (CD134) administration to nonhuman primates: immunostimulatory effects and toxicokinetic study | Q79298134 |
| | Safety and tolerability of antagonist anti-human CD40 Mab ch5D12 in patients with moderate to severe Crohn's disease | Q80360895 |
| | CD137 is expressed in human atherosclerosis and promotes development of plaque inflammation in hypercholesterolemic mice | Q80733397 |
| | Anti-BR3 antibodies: a new class of B-cell immunotherapy combining cellular depletion and survival blockade | Q80768340 |
| | OX40 (CD134) expression in sentinel lymph nodes correlates with prognostic features of primary melanomas | Q80977921 |
| | Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease | Q81640268 |
| | Targeting the LIGHT-HVEM pathway | Q37598573 |
| | Targeting CD30/CD30L in oncology and autoimmune and inflammatory diseases | Q37598579 |
| | Tumor Necrosis Factor-related apoptosis-inducing ligand (TRAIL) Receptor-1 and Receptor-2 agonists for cancer therapy | Q37621564 |
| | Novel functions of RANK(L) signaling in the immune system | Q37641877 |
| | Tumor necrosis factor receptor/tumor necrosis factor family members in antiviral CD8 T-cell immunity | Q37727208 |
| | Glucocorticoid‐Induced TNFR‐Related (GITR) Protein and Its Ligand in Antitumor Immunity: Functional Role and Therapeutic Modulation | Q37799255 |
| | Insights into TL1A and IBD Pathogenesis | Q37820354 |
| | Anti-GITR antibodies--potential clinical applications for tumor immunotherapy | Q37820485 |
| | Decoy receptor 3: a pleiotropic immunomodulator and biomarker for inflammatory diseases, autoimmune diseases and cancer. | Q37835892 |
| | Therapeutic targeting of CD95 and the TRAIL death receptors | Q37901478 |
| | Conatumumab: a novel monoclonal antibody against death receptor 5 for the treatment of advanced malignancies in adults | Q37923958 |
| | The role of core TNF/LIGHT family members in lymph node homeostasis and remodeling | Q37948122 |
| | OX40 and CD30 signals in CD4+ T‐cell effector and memory function: a distinct role for lymphoid tissue inducer cells in maintaining CD4+ T‐cell memory but not effector function | Q37948124 |
| | T‐cell intrinsic effects of GITR and 4‐1BB during viral infection and cancer immunotherapy | Q37948129 |
| | TRAIL signaling and synergy mechanisms used in TRAIL-based combination therapies | Q37974875 |
| | The TWEAK/Fn14 pathway as an aggravating and perpetuating factor in inflammatory diseases; focus on inflammatory bowel diseases | Q38016615 |
| | Role of TWEAK in lupus nephritis: A bench-to-bedside review | Q38021183 |
| | Targeting 4-1BB costimulation to disseminated tumor lesions with bi-specific oligonucleotide aptamers. | Q38332777 |
| | Novel function of B cell-activating factor in the induction of IL-10-producing regulatory B cells | Q38345998 |
| | Immunohistochemical analysis of primary breast tumors and tumor-draining lymph nodes by means of the T-cell costimulatory molecule OX-40. | Q38464262 |
| | Preliminary assessment of the safety and efficacy of tanezumab in Japanese patients with moderate to severe osteoarthritis of the knee: a randomized, double-blind, dose-escalation, placebo-controlled study | Q38482622 |
| | Long-term open-label study of tanezumab for moderate to severe osteoarthritic knee pain | Q38495635 |
| | The anti-Fn14 antibody BIIB036 inhibits tumor growth in xenografts and patient derived primary tumor models and enhances efficacy of chemotherapeutic agents in multiple xenograft models | Q39336527 |
| | Targeting of 4-1BB by monoclonal antibody PF-05082566 enhances T-cell function and promotes anti-tumor activity | Q39381907 |
| | Development and characterization of APRIL antagonistic monoclonal antibodies for treatment of B-cell lymphomas | Q39547912 |
| | Long-Term Hepatic Allograft Acceptance Based on CD40 Blockade by ASKP1240 in Nonhuman Primates | Q39640425 |
| | Treatment with anti-CD137 mAbs causes intense accumulations of liver T cells without selective antitumor immunotherapeutic effects in this organ | Q39723178 |
| | Combining radiotherapy with APO010 in cancer treatment | Q39874751 |
| | Denosumab prevents metacarpal shaft cortical bone loss in patients with erosive rheumatoid arthritis | Q39882954 |
| | Comparative analysis of the expression patterns of various TNFSF/TNFRSF in atherosclerotic plaques | Q39969894 |
| | Pharmacokinetics and biological activity of atacicept in patients with rheumatoid arthritis | Q40119794 |
| | Glucocorticoid-induced tumour necrosis factor receptor-related protein-mediated macrophage stimulation may induce cellular adhesion and cytokine expression in rheumatoid arthritis | Q40159370 |
| | Engineered anti-CD70 antibody with multiple effector functions exhibits in vitro and in vivo antitumor activities | Q40220612 |
| | Human anti-CD40 antagonist antibody triggers significant antitumor activity against human multiple myeloma | Q40402220 |
| | B-cell-derived lymphotoxin promotes castration-resistant prostate cancer | Q40440899 |
| | Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. | Q40456758 |
| | Development of a chimeric anti-CD40 monoclonal antibody that synergizes with LEA29Y to prolong islet allograft survival. | Q40459668 |
| | Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma cells: clinical implications | Q40566183 |
| | Efficacy and safety of ABI793, a novel human anti-human CD154 monoclonal antibody, in cynomolgus monkey renal allotransplantation | Q40578442 |
| | Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. | Q40590332 |
| | Antitumor efficacy of TRA-8 anti-DR5 monoclonal antibody alone or in combination with chemotherapy and/or radiation therapy in a human breast cancer model | Q40632094 |
| | Presence of the T-cell activation marker OX-40 on tumor infiltrating lymphocytes and draining lymph node cells from patients with melanoma and head and neck cancers | Q40880445 |
| | Modulation of T-cell-mediated immunity in tumor and graft-versus-host disease models through the LIGHT co-stimulatory pathway | Q40896166 |
| | Anti-CD30 (BER=H2) immunotoxins containing the type-1 ribosome-inactivating proteins momordin and PAP-S (pokeweed antiviral protein from seeds) display powerful antitumour activity against CD30+ tumour cells in vitro and in SCID mice | Q40949241 |
| | APRIL (TNFSF13) regulates collagen-induced arthritis, IL-17 production and Th2 response | Q42574976 |
| | In Vivo Depletion of Lymphotoxin-Alpha Expressing Lymphocytes Inhibits Xenogeneic Graft-versus-Host-Disease | Q27307168 |
| | Etanercept for active Crohn's disease: A randomized, double-blind, placebo-controlled trial | Q28202166 |
| | The TNF and TNF receptor superfamilies: integrating mammalian biology | Q28203717 |
| | Constitutive Expression of LIGHT on T Cells Leads to Lymphocyte Activation, Inflammation, and Tissue Destruction | Q28206179 |
| | Co-stimulatory members of the TNFR family: keys to effective T-cell immunity? | Q28207052 |
| | A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus | Q28254310 |
| | Denosumab for prevention of fractures in postmenopausal women with osteoporosis | Q28254528 |
| | TACI is mutant in common variable immunodeficiency and IgA deficiency | Q28260786 |
| | Bench to bedside: elucidation of the OPG–RANK–RANKL pathway and the development of denosumab | Q28265584 |
| | Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial | Q28304807 |
| | APRIL-deficient mice have normal immune system development | Q28511017 |
| | CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans | Q29614348 |
| | Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2 | Q29620608 |
| | Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412 | Q29622893 |
| | B Cell Maturation Antigen Deficiency Exacerbates Lymphoproliferation and Autoimmunity in Murine Lupus | Q30426692 |
| | TWEAK/Fn14 pathway: an immunological switch for shaping tissue responses | Q33352379 |
| | Cytokine-mediated disruption of lymphocyte trafficking, hemopoiesis, and induction of lymphopenia, anemia, and thrombocytopenia in anti-CD137-treated mice | Q33374623 |
| | The effect of anti-CD40 ligand in immune thrombocytopenic purpura | Q33378961 |
| | Randomized phase II study of dulanermin in combination with paclitaxel, carboplatin, and bevacizumab in advanced non-small-cell lung cancer | Q33397708 |
| | A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer | Q33401816 |
| | A novel form of 4-1BBL has better immunomodulatory activity than an agonistic anti-4-1BB Ab without Ab-associated severe toxicity | Q33586493 |
| | Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer | Q33658593 |
| | An Fcγ Receptor-Dependent Mechanism Drives Antibody-Mediated Target-Receptor Signaling in Cancer Cells | Q33798802 |
| | A phase I multidose study of dacetuzumab (SGN-40; humanized anti-CD40 monoclonal antibody) in patients with multiple myeloma | Q33829132 |
| | Control of immunity by the TNFR-related molecule OX40 (CD134) | Q33899607 |
| | The strength of the Fas ligand signal determines whether hepatocytes act as type 1 or type 2 cells in murine livers | Q34001849 |
| | BAFF Promotes Th17 Cells and Aggravates Experimental Autoimmune Encephalomyelitis | Q34012753 |
| | Polymorphic variants of LIGHT (TNF superfamily-14) alter receptor avidity and bioavailability | Q34065607 |
| | The molecular architecture of the TNF superfamily | Q34109796 |
| | Targeting pancreatic and ovarian carcinomas using the auristatin-based anti-CD70 antibody–drug conjugate SGN-75 | Q34122802 |
| | Loss of TACI causes fatal lymphoproliferation and autoimmunity, establishing TACI as an inhibitory BLyS receptor | Q34178508 |
| | cAC10-vcMMAE, an anti-CD30–monomethyl auristatin E conjugate with potent and selective antitumor activity | Q34192806 |
| | The many roles of FAS receptor signaling in the immune system | Q34205697 |
| | Serious pulmonary toxicity in patients with Hodgkin's lymphoma with SGN-30, gemcitabine, vinorelbine, and liposomal doxorubicin is associated with an FcγRIIIa-158 V/F polymorphism | Q34231085 |
| | Accelerated central nervous system autoimmunity in BAFF-receptor-deficient mice | Q34231528 |
| | CD137-mediated pathogenesis from chronic hepatitis to hepatocellular carcinoma in hepatitis B virus-transgenic mice | Q36697649 |
| | TRAIL death receptors and cancer therapeutics | Q36714168 |
| | Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma | Q36822162 |
| | CD40-specific costimulation blockade enhances neonatal porcine islet survival in nonhuman primates. | Q36835864 |
| | Blockade of cytotoxic T-lymphocyte antigen-4 as a new therapeutic approach for advanced melanoma | Q37014061 |
| | Tumor necrosis factor antagonist mechanisms of action: a comprehensive review | Q37043901 |
| | The TWEAK-Fn14 cytokine-receptor axis: discovery, biology and therapeutic targeting | Q37135363 |
| | Targeting tumors with LIGHT to generate metastasis-clearing immunity | Q37175025 |
| | Inhibition of the lymphotoxin pathway as a therapy for autoimmune disease | Q37211265 |
| | Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/Tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL). | Q37221909 |
| | Phase I study of the anti-CD40 humanized monoclonal antibody lucatumumab (HCD122) in relapsed chronic lymphocytic leukemia | Q37257024 |
| | T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model. | Q37262424 |
| | TNF superfamily: costimulation and clinical applications | Q37266849 |
| | The role of TNF superfamily members in T-cell function and diseases | Q37332068 |
| | The BLyS family: toward a molecular understanding of B cell homeostasis | Q37335169 |
| | Origins and functional basis of regulatory CD11c+CD8+ T cells | Q37356106 |
| | The risk of infections with biologic therapies for rheumatoid arthritis | Q37360691 |
| | CD40 and autoimmunity: the dark side of a great activator. | Q37365433 |
| | Atacicept in relapsed/refractory multiple myeloma or active Waldenström's macroglobulinemia: a phase I study | Q37400568 |
| | TL1A and DR3, a TNF family ligand‐receptor pair that promotes lymphocyte costimulation, mucosal hyperplasia, and autoimmune inflammation | Q37438611 |
| | Timing and tuning of CD27-CD70 interactions: the impact of signal strength in setting the balance between adaptive responses and immunopathology | Q37474941 |
| | Cracking the BAFF code. | Q37517172 |
| | CD95, BIM and T cell homeostasis | Q37526364 |
| | Antibodies to TWEAK receptor inhibit human tumor growth through dual mechanisms | Q42830477 |
| | Functional expression of 4-1BB (CD137) in the inflammatory tissue in Crohn's disease | Q43416020 |
| | The effect of a single dose of osteoprotegerin in postmenopausal women | Q43520860 |
| | Targeted depletion of lymphotoxin-alpha-expressing TH1 and TH17 cells inhibits autoimmune disease | Q44118287 |
| | A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases | Q44291815 |
| | Molecular Pathways: Osteoclast-Dependent and Osteoclast-Independent Roles of the RANKL/RANK/OPG Pathway in Tumorigenesis and Metastasis | Q44486779 |
| | 4-1BB-mediated immunotherapy of rheumatoid arthritis. | Q45078356 |
| | Blocking the effects of NGF as a route to safe and effective pain relief – fact or fancy? | Q45162445 |
| | Safety, pharmacokinetics and pharmacodynamics of atacicept in healthy volunteers | Q45164056 |
| | A BAFF antagonist suppresses experimental autoimmune encephalomyelitis by targeting cell-mediated and humoral immune responses | Q45302161 |
| | Atacicept in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor antagonist therapy: Results of a phase II, randomized, placebo-controlled, dose-finding trial | Q46071397 |
| | Tanezumab for the Treatment of Pain from Osteoarthritis of the Knee | Q46259879 |
| | Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial | Q46353641 |
| | Role of glucocorticoid-induced TNF receptor family gene (GITR) in collagen-induced arthritis | Q46624594 |
| | Lymphocyte activation antigen CD70 expressed by renal cell carcinoma is a potential therapeutic target for anti-CD70 antibody-drug conjugates | Q46952775 |
| | Serum OX40 ligand levels in asthmatic children: A potential biomarker of severity and persistence | Q46978639 |
| | A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma. | Q47731944 |
| | Development of a human monoclonal antibody for potential therapy of CD27-expressing lymphoma and leukemia | Q47758962 |
| | Serum concentrations of soluble 4-1BB and 4-1BB ligand correlated with the disease severity in rheumatoid arthritis | Q47923806 |
| | Osteoprotegerin deficiency and juvenile Paget's disease | Q48292818 |
| | Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. | Q48851709 |
| | Treatment with chimeric anti-human CD40 antibody suppresses MRI-detectable inflammation and enlargement of pre-existing brain lesions in common marmosets affected by MOG-induced EAE. | Q48892230 |
| | Phenotypic characterization of early onset Paget's disease of bone caused by a 27-bp duplication in the TNFRSF11A gene | Q50482693 |
| | Identification of a novel tandem duplication in exon 1 of the TNFRSF11A gene in two unrelated patients with familial expansile osteolysis | Q50484870 |
| | Tanezumab Reduces Osteoarthritic Knee Pain: Results of a Randomized, Double-Blind, Placebo-Controlled Phase III Trial | Q51326054 |
| | First-line treatment of metastatic or locally advanced unresectable soft tissue sarcomas with conatumumab in combination with doxorubicin or doxorubicin alone: a phase I/II open-label and double-blind study | Q51452174 |
| | Development, validation and application of ELISAs for pharmacokinetic and HACA assessment of a chimeric anti-CD40 monoclonal antibody in human serum | Q51771655 |
| | A phase II study of SGN-30 in cutaneous anaplastic large cell lymphoma and related lymphoproliferative disorders | Q51789300 |
| | Cutting edge: the dependence of plasma cells and independence of memory B cells on BAFF and APRIL. | Q51966554 |
| | A phase I study of dacetuzumab (SGN-40, a humanized anti-CD40 monoclonal antibody) in patients with chronic lymphocytic leukemia | Q53351927 |
| | Phase I clinical study of atacicept in patients with relapsed and refractory B-cell non-Hodgkin's lymphoma | Q53497567 |
| | Survival in human colorectal cancer correlates with expression of the T-cell costimulatory molecule OX-40 (CD134). | Q53669679 |
| | Interleukin-13 damages intestinal mucosa via TWEAK and Fn14 in mice-a pathway associated with ulcerative colitis | Q54350603 |
| | TNF Conference 2009: Beyond Bones – RANKL/RANK in the Immune System | Q57184195 |
| | High serum levels of B-lymphocyte stimulator are associated with clinical?pathological features and outcome in classical Hodgkin lymphoma | Q58883556 |
| | Increased Soluble 4-1BB Ligand (4-1BBL) Levels in Peripheral Blood of Patients with Multiple Sclerosis | Q60187909 |
| | Response of refractory Hodgkin's disease to monoclonal anti-CD30 immunotoxin | Q67516432 |
| | A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis | Q73114791 |
| | Prevention of kidney allograft rejection using anti-CD40 and anti-CD86 in primates | Q73134598 |
| | Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand | Q73401367 |
| | A humanized anti--4-1BB monoclonal antibody suppresses antigen-induced humoral immune response in nonhuman primates | Q73458018 |
| | Phase I clinical trial of a monoclonal antibody against CD40-ligand (IDEC-131) in patients with systemic lupus erythematosus | Q73483737 |
| | Differential use of Fas ligand and perforin cytotoxic pathways by donor T cells in graft-versus-host disease and graft-versus-leukemia effect | Q73785060 |
| | A soluble form of CD137 (ILA/4-1BB), a member of the TNF receptor family, is released by activated lymphocytes and is detectable in sera of patients with rheumatoid arthritis | Q74251717 |
| | The anti-CD30 monoclonal antibody SGN-30 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin's disease | Q74409841 |
| | Expansile Skeletal Hyperphosphatasia Is Caused by a 15-Base Pair Tandem Duplication inTNFRSF11AEncoding RANK and Is Allelic to Familial Expansile Osteolysis | Q77435071 |
| | Therapeutic effect of an anti-Fas ligand mAb on lethal graft-versus-host disease | Q77849981 |
| | TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group | Q78130683 |
| | LIGHT is constitutively expressed on T and NK cells in the human gut and can be induced by CD2-mediated signaling | Q34382093 |
| | A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphoma | Q34433792 |
| | Targeting the lymphotoxin-beta receptor with agonist antibodies as a potential cancer therapy | Q34571305 |
| | Immune modulation with weekly dosing of an agonist CD40 antibody in a phase I study of patients with advanced solid tumors | Q34616576 |
| | Enhancement of anti-tumor immunity through local modulation of CTLA-4 and GITR by dendritic cells | Q34633278 |
| | Reverse signaling initiated from GITRL induces NF-kappaB activation through ERK in the inflammatory activation of macrophages | Q34643967 |
| | APO010, a synthetic hexameric CD95 ligand, induces human glioma cell death in vitro and in vivo | Q34722539 |
| | Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression | Q34831296 |
| | The tumor necrosis factor family member LIGHT is a target for asthmatic airway remodeling | Q34989767 |
| | Therapeutic interventions targeting CD40L (CD154) and CD40: the opportunities and challenges | Q35003473 |
| | Tumor necrosis factor blockade and the risk of viral infection | Q35161630 |
| | The Biology of TRAIL and the Role of TRAIL-Based Therapeutics in Infectious Diseases | Q35172090 |
| | Preclinical pharmacokinetics, pharmacodynamics, and activity of a humanized anti-CD40 antibody (SGN-40) in rodents and non-human primates | Q35546416 |
| | Development of an Fn14 agonistic antibody as an anti-tumor agent | Q35556794 |
| | TNF Superfamily Networks: bidirectional and interference pathways of the herpesvirus entry mediator (TNFSF14) | Q35567956 |
| | A lymphotoxin-driven pathway to hepatocellular carcinoma | Q35575883 |
| | Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial | Q35638718 |
| | The TWEAK-Fn14 System: Breaking the Silence of Cytokine-Induced Skeletal Muscle Wasting | Q35671234 |
| | The discovery and development of belimumab: the anti-BLyS–lupus connection | Q35691272 |
| | Dispensability of APRIL to the development of systemic lupus erythematosus in NZM 2328 mice | Q35798968 |
| | TNF superfamily in inflammatory disease: translating basic insights | Q35821666 |
| | Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease | Q36007685 |
| | The signaling networks of the herpesvirus entry mediator (TNFRSF14) in immune regulation | Q36053977 |
| | Network communications: lymphotoxins, LIGHT, and TNF. | Q36072461 |
| | Safety, pharmacokinetics, and biologic activity of pateclizumab, a novel monoclonal antibody targeting lymphotoxin α: results of a phase I randomized, placebo-controlled trial | Q36084891 |
| | Pharmacological modulation of GITRL/GITR system: therapeutic perspectives. | Q36147260 |
| | Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension | Q36153179 |
| | In vivo blockade of OX40 ligand inhibits thymic stromal lymphopoietin driven atopic inflammation | Q36173559 |
| | A soluble form of B cell maturation antigen, a receptor for the tumor necrosis factor family member APRIL, inhibits tumor cell growth | Q36368318 |
| | OX40 (CD134) controls memory T helper 2 cells that drive lung inflammation | Q36371325 |
| | Effect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial | Q36508404 |
| | A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies | Q36508806 |
| | Expression of TweakR in breast cancer and preclinical activity of enavatuzumab, a humanized anti-TweakR mAb. | Q36546646 |
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | TNF | Q18032037 |
| P304 | page(s) | 147-168 | |
| P577 | publication date | 2013-01-21 | |
| P13046 | publication type of scholarly work | review article | Q7318358 |
| P1433 | published in | Nature Reviews Drug Discovery | Q45998 |
| P1476 | title | Clinical targeting of the TNF and TNFR superfamilies | |
| P478 | volume | 12 | |